TACSTD2 and triple-negative breast carcinoma: Sacituzumab govitecan has been approved for the treatment of patients with triple-negative breast cancer on the basis of the results of clinical trials that have been conducted with no biomarker selection, as TROP2 expression is reportedly observed in >85% of these patients [42].